

[Request Information](#)

[Permalink](#)

Nanoparticle Therapeutic Vaccines for Cancer Treatment

Tech ID: 33994 / UC Case 2025-764-0

BRIEF DESCRIPTION

A cutting-edge vaccine delivery platform that enhances tumor treatment by co-delivering MHC class I and II restricted antigens.

FULL DESCRIPTION

This technology represents a novel approach in the field of immunotherapy, specifically designed to combat aggressive cancers such as melanoma and colon carcinoma. By utilizing nanoparticles to simultaneously deliver both MHC class I and II restricted tumor antigens, this platform aims to induce a more potent and specific anti-tumor immune response. This method addresses the limitations of current cancer treatments by focusing on the activation and persistence of cytotoxic T cells, thereby offering a promising strategy for the treatment of persistent cancers.

SUGGESTED USES

- » Development of more effective cancer vaccines targeting both major T cell subsets for the treatment of melanoma and other aggressive cancers.
- » Advancement in immunotherapy approaches by providing a more targeted and sustained anti-tumor immune response.
- » Potential for application in a wide range of cancer types, due to the universal strategy of targeting MHC class I and II restricted antigens.

ADVANTAGES

- » Improves anti-tumor immune response through co-delivery of MHC class I and II melanoma tumor-associated antigens.
- » Enhances treatment efficacy over single-antigen nanoparticles by simultaneously delivering both MHC classes of tumor-associated antigens, demonstrating the importance of dual-antigen design.
- » Alleviates severe side-effects associated with current cancer therapies such as radioactive therapy.

PATENT STATUS

Patent Pending

CONTACT

Alvin Viray
aviray@uci.edu
tel: 949-824-3104.



OTHER INFORMATION

CATEGORIZED AS

- » **Biotechnology**
 - » Health
- » **Medical**
 - » Delivery Systems
 - » Disease: Cancer
 - » Therapeutics
 - » Vaccines
- » **Nanotechnology**
 - » NanoBio
- » **Research Tools**
 - » Antibodies

RELATED CASES

2025-764-0

UCI Beall
Applied Innovation

5270 California Avenue / Irvine, CA
92697-7700 / Tel: 949.824.2683



© 2025, The Regents of the University of
California
[Terms of use](#)
[Privacy Notice](#)